Provider Alert! New prior authorization requirements for Burosumab-Twza(Crysvita)
Attention: Nephrologists and Endocrinologists Effective Date: 1/6/2021 Call to action: Texas Children’s Health Plan (TCHP) is aligning prior authorization criteria for burosumab-twza (Crysvita), J0584, with the Texas Medicaid Provider Procedures Manual (TMPPM). Crysvita is a clinician administered drug indicated for members with X-linked hypophosphatemia (XLH) and Fibroblast Growth Factor 23 (FGF23)-related hypophosphatemia. Below are the new prior authorization criteria for TCHP members effective 01/06/2021. For initial therapy, the following criteria must be met: The client has a diagnosis of X-linked hypophosphatemia (XLH)...
